Cookies

Like most websites The Medicine Maker uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Discovery & Development Drug Delivery, Formulation, Vaccines, Ingredients

The Argument for Albumin

Increasingly, the industry is seeing a move away from proteins and peptides towards even more complex drugs, such as antibody drug conjugates, new viral vaccines and cell-based therapies. Of course, such therapies come hand in hand with greater formulation challenges – and in many cases standard formulation technologies are no longer up to scratch. For example, lipids present in vaccine and cell-based therapies can be broken up by standard excipient approaches, while products that require high concentrations, such as antibodies, can be limited by viscosity issues. The incidence of multiple problems, such as aggregation and oxidation occurring simultaneously, is also common in more advanced biopharma products.

In my view, the use of albumin is very effective in formulating complicated products. The stabilization properties of human-serum derived albumin were once well recognized in the industry, but with issues such as Creutzfeldt-Jakob disease and AIDS, serum-derived albumin use declined due to the potential risks. Today, with the availability of recombinant albumin, these risks are eliminated. However, as the industry has moved away from the use of albumin (instead using sugars, amino acids and detergents), many in industry have forgotten the benefits that albumin can bring. It is time to reacquainte the industry with the benefits of albumin. There really is so much to explore that companies are perhaps unaware of, particularly when it comes to early development.

Enjoy our FREE content!

Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE and always will be!

Login if you already created an account

Or register now - it’s free and always will be!

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine
Register

Or Login as a Guest or via Social Media

About the Author

Phil Morton

Phil Morton is Chief Technology Officer at Albumedix.

Register here

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine

Register

December Issue of The Medicine Maker